Seeking Alpha

Cubist Pharmaceuticals (CBST -3%) slips on a mixed Q3 report yesterday, beating on its EPS but...

Cubist Pharmaceuticals (CBST -3%) slips on a mixed Q3 report yesterday, beating on its EPS but missing on revenue estimates. Net earnings rose 66% Y/Y as the company continued to see strong growth for its intravenous antibiotic Cubicin, but it also cut guidance going forward. The bio-pharmaceutical developer now sees revenue in the range of $915M - $931M, below Street estimates of $931M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|